Drug Monograph

Drug/Drug Class:	**Dutoprol (metoprolol succinate extended release and hydrochlorothiazide) Tablet / Beta-Blocker and Diuretic**
Prepared for:	MO HealthNet
Prepared by:	ACS, A Xerox Company

☒ **New Criteria** ☐ **Revision of Existing Criteria**

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Each tablet of Dutoprol 25/12.5 mg contains 23.75 mg of metoprolol succinate extended release equivalent to 25 mg of metoprolol tartrate and 12.5 mg of hydrochlorothiazide. Each tablet of Dutoprol 50/12.5 mg contains 47.5 mg of metoprolol succinate extended release equivalent to 50 mg of metoprolol tartrate and 12.5 mg of hydrochlorothiazide. Each tablet of Dutoprol 100/12.5 mg contains 95 mg of metoprolol succinate extended release equivalent to 100 mg of metoprolol tartrate and 12.5 mg of hydrochlorothiazide.
Manufacturer:	**AstraZeneca Pharmaceuticals LP** 1800 Concord Pike Wilmington, DE 19897
Indications:	Dutoprol tablets are indicated for the management of hypertension. The fixed-dose combination is not indicated for initial therapy.
Costs:	$0.53 per tablet of all strengths of Dutoprol Wholesale Acquisition Cost
Summary of Findings:	This drug is being considered for inclusion in the state specific Preferred Drug List (PDL).
Status Recommendation:	☐ Prior Authorization (PA) Required ☐ Open Access ☐ Clinical Edit ☒ PDL
Type of PA Criteria:	☐ Increased Risk of ADE ☐ Preferred Agent ☐ Appropriate Indications ☒ Under Solicitation

Prepared By: Katie Wilbers, Pharm.D.
Date: February 28, 2012